A Phase I Study of BMS-641988 in Japanese Patients With Castration Resistant Prostate Cancer
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
To assess the safety and tolerability of BMS-641988 once daily orally in Japanese patients with castration resistant prostate cancer
throughout the study
Yes
Bristol-Myers Squibb
Study Director
Bristol-Myers Squibb
Japan: Pharmaceuticals and Medical Devices Agency
CA185-005
NCT00644488
July 2008
March 2009
Name | Location |
---|